• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell . COVID-19-neutralizing antibodies predict disease severity and survival

tetano

Editor, Senior Moderator
Cell


. 2020 Dec 15;S0092-8674(20)31685-8.
doi: 10.1016/j.cell.2020.12.015. Online ahead of print.
COVID-19-neutralizing antibodies predict disease severity and survival


Wilfredo F Garcia-Beltran[SUP] 1 [/SUP], Evan C Lam[SUP] 2 [/SUP], Michael G Astudillo[SUP] 1 [/SUP], Diane Yang[SUP] 1 [/SUP], Tyler E Miller[SUP] 1 [/SUP], Jared Feldman[SUP] 2 [/SUP], Blake M Hauser[SUP] 2 [/SUP], Timothy M Caradonna[SUP] 2 [/SUP], Kiera L Clayton[SUP] 2 [/SUP], Adam D Nitido[SUP] 2 [/SUP], Mandakolathur R Murali[SUP] 3 [/SUP], Galit Alter[SUP] 2 [/SUP], Richelle C Charles[SUP] 4 [/SUP], Anand Dighe[SUP] 1 [/SUP], John A Branda[SUP] 1 [/SUP], Jochen K Lennerz[SUP] 1 [/SUP], Daniel Lingwood[SUP] 2 [/SUP], Aaron G Schmidt[SUP] 2 [/SUP], A John Iafrate[SUP] 1 [/SUP], Alejandro B Balazs[SUP] 5 [/SUP]



Affiliations

Abstract

Coronavirus disease 2019 (COVID-19) exhibits variable symptom severity ranging from asymptomatic to life-threatening, yet the relationship between severity and the humoral immune response is poorly understood. We examined antibody responses in 113 COVID-19 patients and found that severe cases resulting in intubation or death exhibited increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high anti-receptor binding domain (RBD) antibody levels. Although anti-RBD immunoglobulin G (IgG) levels generally correlated with neutralization titer, quantitation of neutralization potency revealed that high potency was a predictor of survival. In addition to neutralization of wild-type SARS-CoV-2, patient sera were also able to neutralize the recently emerged SARS-CoV-2 mutant D614G, suggesting cross-protection from reinfection by either strain. However, SARS-CoV-2 sera generally lacked cross-neutralization to a highly homologous pre-emergent bat coronavirus, WIV1-CoV, which has not yet crossed the species barrier. These results highlight the importance of neutralizing humoral immunity on disease progression and the need to develop broadly protective interventions to prevent future coronavirus pandemics.

Keywords: COVID-19; D614G; ELISA; RBD; SARS-CoV-2; WIV1-CoV; disease severity; neutralizing antibodies; pro-inflammatory cytokines; spike.
 
Back
Top Bottom